FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria di Stack

Joint Regeneration Stack

Recovery & Healingintermediate

85

sintesi

85
Share
Peptidi

3

Media giornaliera mcg

3,500

Livello

intermediate

Aggiunto

May 17, 2026

Panoramica

The Joint Regeneration Stack builds upon the foundational Wolverine Stack by adding GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex), a naturally occurring tripeptide-copper complex that declines significantly with age. GHK-Cu is one of the most studied peptides for tissue remodeling, with over 60 published studies demonstrating its ability to stimulate collagen synthesis, attract immune cells to sites of damage, promote glycosaminoglycan production, and modulate metalloproteinase activity — all critical processes for joint cartilage maintenance and repair. BPC-157 contributes its characteristic angiogenic and growth-factor-modulating properties, creating improved blood supply to hypovascular joint tissues such as cartilage and menisci, which normally receive limited circulation. TB-500 provides systemic anti-inflammatory effects and promotes cellular migration, ensuring repair cells can reach deep joint structures. The addition of GHK-Cu specifically targets the extracellular matrix remodeling that is essential for cartilage and synovial tissue regeneration. The three-peptide synergy addresses joint degeneration from multiple angles simultaneously: BPC-157 restores vascular supply and growth factor signaling, TB-500 reduces chronic inflammation and enables cellular trafficking, and GHK-Cu directly stimulates the synthesis of collagen type II, proteoglycans, and other structural components of articular cartilage. This makes the stack particularly suitable for individuals with degenerative joint conditions, chronic tendinopathy, or those recovering from joint injuries where simple rest and anti-inflammatories have proven insufficient. The intermediate classification reflects the three-compound complexity and the need for consistent dosing across different schedules.

Protocollo di Dosaggio

BPC-157

Twice per day· subcutaneous

Leggi di più su BPC-157 →

250 mcg

per dose

TB-500

2x/week· subcutaneous

Leggi di più su TB-500 →

2,500 mcg

per dose

GHK-Cu

Every day· subcutaneous

Leggi di più su GHK-Cu →

500 mcg

per dose

Obiettivi & Evidenze

Joint repairCartilage regenerationInflammationCollagen synthesisMobility
Livello di Evidenza:Studio animale

Avvertenze

  • BPC-157, TB-500 and GHK-Cu were removed from the FDA Category 2 list (April 2026) but remain pending PCAC review — none is approved or legal to compound yet.

Comments

Sign in to join the discussion

Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.